ELAN - Elanco Animal Health Incorporated

NYSE - Nasdaq Real Time Price. Currency in USD
32.72
+1.23 (+3.91%)
As of 3:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close31.49
Open31.80
Bid32.79 x 1400
Ask32.80 x 2200
Day's Range31.70 - 32.88
52 Week Range28.00 - 37.61
Volume1,799,736
Avg. Volume4,376,620
Market Cap11.966B
Beta (3Y Monthly)N/A
PE Ratio (TTM)238.83
EPS (TTM)0.14
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.40
Trade prices are not sourced from all markets
  • Here’s What Hedge Funds Think About Elanco Animal Health Incorporated (ELAN)
    Insider Monkey22 hours ago

    Here’s What Hedge Funds Think About Elanco Animal Health Incorporated (ELAN)

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]

  • Behind the scenes on Aratana’s sale to Elanco
    American City Business Journals15 days ago

    Behind the scenes on Aratana’s sale to Elanco

    A recent SEC filing reveals what led up to the sale of the Leawood animal health company to Elanco last year — and the misperception that Engaged Capital was an interested buyer.

  • Business Wire28 days ago

    New Study Suggests Service Dogs Can Impact Psychosocial Health of Household

    New data published in The American Journal of Occupational Therapy suggests the impact of a service dog may extend beyond the recipient and have positive impacts on family members as well. This study, funded by Elanco Animal Health Incorporated (ELAN) and conducted by Purdue University College of Veterinary Medicine, is the first of its kind using standardized measures to examine the relationship between the human animal bond and psychosocial outcomes among people with service dogs.

  • 6 Positions the Vanguard Health Care Fund Continues to Increase
    GuruFocus.comlast month

    6 Positions the Vanguard Health Care Fund Continues to Increase

    CVS Health tops the list

  • Elanco Animal Health Incorporated (ELAN) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Elanco Animal Health Incorporated (ELAN) Q1 2019 Earnings Call Transcript

    ELAN earnings call for the period ending March 31, 2019.

  • Business Wirelast month

    Elanco Animal Health Reports First Quarter Results

    GREENFIELD, Ind.-- -- Gross margin improved 190 basis points to 53.0 percent of revenue Earnings per share was $0.09 , or $0.25 Revenue declined 1 percent to $731.1 million; Total and Core Revenue both grew 2 percent at constant currency rates Revenue from Innovation portfolio grew 59 percent, represents 13 percent of total revenue Announced agreement to acquire Aratana Therapeutics and collaboration ...

  • Business Wirelast month

    Elanco Appoints Art A. Garcia to Board of Directors

    Elanco Animal Health (ELAN) today announced the appointment of Art A. Garcia, recently retired executive vice president and chief financial officer of Ryder System Inc., to the Board of Directors. The board was established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company.

  • The Vanguard Health Care Fund's Top 5 Buys of the 1st Quarter
    GuruFocus.com2 months ago

    The Vanguard Health Care Fund's Top 5 Buys of the 1st Quarter

    Health care-oriented fund’s top buys include one new holding and four position boosts

  • David Carlson Buys 2 Stocks, Sells 1 in 1st Quarter
    GuruFocus.com2 months ago

    David Carlson Buys 2 Stocks, Sells 1 in 1st Quarter

    Guru invests in Elanco Animal Health and newly public Lyft

  • GlobeNewswire2 months ago

    MERGER ALERT – PETX and SRMC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, April 30, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.

  • Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
    Zacks2 months ago

    Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut

    Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.

  • The 10 Best Health Care Stocks to Buy for 2019
    Kiplinger2 months ago

    The 10 Best Health Care Stocks to Buy for 2019

    Health care stocks were the best sector in the Standard & Poor's 500-stock index in 2018, according to Yardeni Research. The sector's 4.7% gain last year isn't exactly eye-popping. But consider that utilities (+0.5%) were the only sector in the black, and that the index itself lost 6.2% ... and you realize just how impressive health care actually was.As we look ahead to 2019, economic storm clouds appear to be gathering. Although a recession is unlikely in the year ahead, UCLA economists estimate that GDP growth will shrink from 3% in 2018 to 2% in 2019 and finally 1% in 2020.Thus, in the potential absence of a good offense, it makes sense for investors to buy some defense in 2019. The best health care stocks can fit that bill. "Health care is a defensive growth sector that we think should have a growth upturn over the next five years or so," Saira Malik, head of global equities at Nuveen, told Fortune in November.With that in mind, here are 10 health care stocks to buy for 2019. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond

  • GlobeNewswire2 months ago

    Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Aratana Therapeutics, Inc. (PETX) on Behalf of Stockholders and Encourages PETX Investors to Contact the Firm

    NEW YORK, April 29, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Aratana Therapeutics, Inc. (NASDAQ: PETX) on.

  • Business Wire2 months ago

    Elanco Confirms Date and Conference Call for First Quarter 2019 Financial Results Announcement

    Elanco Animal Health (ELAN) will announce its first quarter 2019 financial results on Thursday, May 9, 2019. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. Eastern time.

  • GlobeNewswire2 months ago

    QTNA, PETX, and SFS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

    WILMINGTON, Del., April 29, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Quantenna Communications, Inc. (NYSE: QTNA) regarding possible breaches.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Aratana Therapeutics, Inc. to Elanco Animal Health Incorporated is Fair to Shareholders

    NEW YORK, April 29, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Aratana Therapeutics, Inc..

  • PR Newswire2 months ago

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics, Inc.

    NEW YORK , April 26, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Aratana Therapeutics, Inc. (NASDAQ: PETX) and its board of directors for breach of fiduciary duty concerning ...

  • Benzinga2 months ago

    Elanco Animal Health Announces $245M Stock-For-Stock Acquisition Of Aratana Therapeutics

    Elanco Animal Health Inc (NYSE: ELAN) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX). The stock-for-stock deal is worth as much as $245 million, Elanco said. The deal would grant Aratana shareholders 0.1481 Elanco shares and one cash contingent value right for each Aratana share, and the shares to be issued represent about 2 percent of outstanding Elanco shares.

  • TheStreet.com2 months ago

    News Surrounds 3 Small Biotechs, With a Merger Claiming One

    First-quarter earnings reports are flooding the wires this week and both the Nasdaq and S&P 500 have attained all-time highs. The space has been hurt by political rhetoric as the 2020 election cycle starts to get in full swing. Let's consider a few biotech names and start on a high note.

  • Aratana Therapeutics will sell for $245M to big animal health player
    American City Business Journals2 months ago

    Aratana Therapeutics will sell for $245M to big animal health player

    The Leawood pet drug company, founded in 2010, was the metro area's fastest-growing company last year.

  • MarketWatch2 months ago

    Animal health giant Elanco to acquire Aratana Therapeutics

    Shares of Aratana Therapeutics shot up 39% in premarket trade on Friday after Elanco Animal Health announced it would be acquiring the pet therapeutics company in a deal worth up to $245 million. For each share of Aratana, shareholders will receive 0.1481 shares of Elanco stock and one contingent value right of 25 cents that will be paid upon meeting certain sales goals. The deal is expected to close by mid-year, the companies said. Shares of Elanco fell 0.7% in premarket trade but are up 2.7% in the year to date, while the S&P 500 is up 16.7%.

  • Business Wire2 months ago

    Elanco Announces Agreement to Acquire Aratana Therapeutics; Completes Oncology Development Agreement with VetDC, Creates Specialty Veterinary Business Focus

    Elanco Animal Health (ELAN) today announced it has signed an agreement to acquire Aratana Therapeutics (PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®. Elanco has also signed a development and commercialization agreement with VetDC for Tanovea®-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment. In conjunction with these agreements, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business focused on bringing new and innovative products to the growing veterinary specialty category.

  • PR Newswire2 months ago

    Aratana Therapeutics to be Acquired by Elanco Animal Health

    LEAWOOD, Kan., April 26, 2019 /PRNewswire/ -- Aratana Therapeutics (PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acquired by Elanco Animal Health (ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. Aratana's field force has demonstrated the ability to technically communicate with veterinarians on pet therapeutics and if the proposed agreement is consummated, the Aratana field force would transition into this commercial team.

  • Were Hedge Funds Right About Dumping Elanco Animal Health Incorporated (ELAN)?
    Insider Monkey2 months ago

    Were Hedge Funds Right About Dumping Elanco Animal Health Incorporated (ELAN)?

    Is Elanco Animal Health Incorporated (NYSE:ELAN) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus […]

  • GuruFocus.com3 months ago

    Top Insider Buys Highlight

    Insiders invest in Fidelity National Information Services, Elanco Animal Health, Alkermes and MDU Resources Group